Evaluation of 41calcium as a new approach to assess changes in bone metabolism: Effect of a bisphosphonate intervention in postmenopausal women with low bone mass

Journal of Bone and Mineral Research

Volumn 22, Issue 10, 2007, Pages 1518-1525

  Denk, Eberhard ^a   Hillegonds, Darren ^b   Hurrell, Richard F ^a   Vogel, John ^b   Fattinger, Karin ^c   Häuselmann, Hans J ^d   Kraenzlin, Marius ^e   Walczyk, Thomas ^a,f  

^a ETH ZURICH   (Switzerland)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d KLINIK IM PARK   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

41Ca; Biomarkers; Bisphosphonate; BMD; Calcium kinetics

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CALCIUM 40; CALCIUM 41; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; ERGOCALCIFEROL; PROCOLLAGEN TYPE 1 PROPEPTIDE; RISEDRONIC ACID; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; DRUG DERIVATIVE; ETIDRONIC ACID;

ACCELERATOR MASS SPECTROMETRY; ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DRUG EFFECT; DRUG RESPONSE; FEMALE; HIP; HUMAN; ISOTOPE LABELING; MASS SPECTROMETRY; MEASUREMENT; OSSIFICATION; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; SIGNAL DETECTION; SPINE; URINALYSIS; AGED; CLINICAL TRIAL; KINETICS; METABOLIC BONE DISEASE; METABOLISM; POSTMENOPAUSE OSTEOPOROSIS; SENSITIVITY AND SPECIFICITY; URINE;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM RADIOISOTOPES; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; KINETICS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; SENSITIVITY AND SPECIFICITY;

EID: 38449092808     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.070617     Document Type: Article

References (34)

1. Nieves JW 2005 Osteoporosis: The role of micronutrients. Am J Clin Nutr 81:1232S-1239S.
2. Sievanen H, Koskue V, Rauhio A, Kannus P, Heinonen A, Vuori I 1998 Peripheral quantitative computed tomography in human long bones: Evaluation of in vitro and in vivo precision. J Bone Miner Res 13:871-882.
3. Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH 2000 Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int 11:467-480.
4. Wastney ME, Ng J, Smith D, Martin BR, Peacock M, Weaver CM 1996 Differences in calcium kinetics between adolescent girls and young women. Am J Physiol 271:R208-R216.
5. 41Calcium isotope for the assessment of changes in bone calcium metabolism. Anal Bioanal Chem 386:1587-1602.
6. Freeman S, Beck B, Bierman JM, Caffee MW, Heaney RP, Holloway L, Marcus R, Southon JR, Vogel JS 2000 The study of skeletal calcium metabolism with Ca-41 and Ca-45. Nucl Instrum Methods Phys Res B 172:930-933.
7. Freeman S, King JC, Vieira NE, Woodhouse LR, Yergey AL 1997 Human calcium metabolism including bone resorption measured with Ca-41 tracer. Nucl Instrum Methods Phys Res B 123:266-270.
8. Johnson RR, Berkovits D, Boaretto E, Gelbart Z, Ghelberg S, Meirav O, Paul M, Prior J, Sossi V, Venczel E 1994 Calcium resorption from bone in a human studied by Ca-41 tracing. Nucl Instrum Methods Phys Res B 92:483-488.
9. 41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients. Clin Chem 51:2095-2102.
10. Fleisch H 1998 Bisphosphonates: Mechanisms of action. Endocr Rev 19:80-100.
11. Nishiizumi K, Caffee MW, DePaolo DJ 2000 Preparation of Ca-41 AMS standards. Nucl Instrum Methods Phys Res B 172:399-403.
12. Hennessy C, Berglund M, Ostermann M, Walczyk T, Synal H-A, Geppert C, Wendt K, Taylor PDP 2005 Certification of a 41Ca dose material for use in human studies (IRMM-3703) and a corresponding set of isotope reference materials for 41Ca measurements (IRMM-3701). Nucl Instrum Methods Phys Res B 229:281-292.
13. Heaney RP 1971 Calcium kinetics in plasma: As they apply to the measurements of bone formation and resorption rates. In: Bourne GH (ed.) Biochemistry and Physiology of Bone, 2 ed. Academic Press, New York, NY, USA, p. 4.
14. Sheiner LB, Rosenberg B, Marathe VV 1977 Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5:445-479.
15. Miller R 2001 Population pharmacokinetics. In: Atkinson AJ (ed.) Principles of Clinical Pharmacology. Academic Press, San Diego, CA, USA, pp. 113-119.
16. Beal S, Sheiner L 1992 NONMEM Users' Guides. NONMEM Project Group, University of California at San Francisco, San Francisco, CA, USA.
17. Lin Y, Hillegonds DJ, Gertz ER, Van Loan MD, Vogel JS 2004 Protocol for assessing bone health in humans by tracing long-lived 41Ca isotope in urine, serum, and saliva samples. Anal Biochem 332:193-195.
18. Schwarz G 1978 Estimating dimension of a model. Ann Statist 6:461-464.
19. Bates DM, Watts DG 1988 Nonlinear Regression Analysis and Its Applications. Wiley, New York, NY, USA.
20. Garnero P, Borel O, Delmas PD 2001 Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694-702.
21. Schmidt-Gayk H, Spanuth E, Kotting J, Bartl R, Felsenberg D, Pfeilschifter J, Raue F, Roth HJ 2004 Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin Chem Lab Med 42:90-95.
22. Gomez B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT 1995 Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560-1566.
23. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103-111.
24. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20:141-151.
25. Leung JY, Ho AY, Ip TP, Lee G, Kung AW 2005 The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: A randomized placebo-controlled study. Bone 36:358-364.
26. Davis JW, Ross PD, Wasnich RD, MacLean CJ, Vogel JM 1991 Long-term precision of bone loss rate measurements among postmenopausal women. Calcif Tissue Int 48:311-318.
27. Lang P, Steiger P, Faulkner K, Glueer C, Genant HK 1991 Osteoporosis. Current techniques and recent developments in quantitative bone densitometry. Radiol Clin North Am 29:49-76.
28. Muller R, Hildebrand T, Hauselmann HJ, Ruegsegger P 1996 In vivo reproducibility of three-dimensional structural properties of noninvasive bone biopsies using 3D-pQCT. J Bone Miner Res 11:1745-1750.
29. Genant HK, Engelke K, Fuerst T, Glueer CC, Grampp S, Harris ST, Jergas M, Lang T, Lu Y, Majumdar S, Mathur A, Takada M 1996 Noninvasive assessment of bone mineral and structure: State of the art. J Bone Miner Res 11:707-730.
30. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20:141-151.
31. Raisz L, Smith JA, Trahiotis M, Fall P, Shoukri K, Digennaro J, Sacco-Gibson N 2000 Short-term risedronate treatment in postmenopausal women: Effects on biochemical markers of bone turnover. Osteoporos Int 11:615-620.
32. Steiniche T, Hauge E 2003 Normal structure and function of bone. In: Yuehuei H, An KLM (eds.) Handbook of Histology Methods for Bone and Cartilage. Humana Press, Totowa, NJ, USA, p. 588.
33. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL 2000 Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100-103.
34. Kamel S, Fardellone P, Meddah B, Lorget-Gondelmann F, Sebert JL, Brazier M 1998 Response of several markers of bone collagen degradation to calcium supplementation in postmenopausal women with low calcium intake. Clin Chem 44:1437-1442.